Description
Details
Ledifos is combination of Ledipasvir and Sofosbuvir.
Ledifos is indicated for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection.Ledifos is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration.
Treating chronic
hepatitis C virus
(HCV) infection in certain patients. Ledifos (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body
Note:
Ledifos is a prescription drug and should be used under proper medical guidance and advice.The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking,check with your doctor,nurse or pharmacist.
keep all medicines out of the reach of children and away from pets,never share your medicines with others,and use this medication only for the indication prescribed.
Hepatitis C virus (HCV) is a major global health problem.
WHO estimates that 71 million people worldwide are chronically infected with HCV. Of those, 2.3 million people are coinfected with the human immunodeficiency virus (HIV) and HCV. In 2015, around 400 000 people died of HCV-related liver disease, and evidence indicates that the HCV burden is increasing.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C.
Combinations of DAAs can cure infection with HCV in 12 weeks, are highly effective and have limited side-effects. Pan-genotypic combinations (that are effective against all genotypes of HCV) have started to become available; they can contribute to the simplification of both the diagnostic and treatment algorithm, which would enable treatment to be rolled out in resource-limited settings.
The market for direct-acting antivirals (DAAs) has significantly changed
in the few years since they were launched. The relative importance of regimens is becoming clearer. New DAAs and combinations thereof continue to be launched, expanding the number of regimens. Nevertheless, to date, sofosbuvir still is the backbone of most regimens.
DAAs are becoming available in more low- and middle-income countries
, although the pace should be quickened. There is still a long way to go until all key products are registered and launched in all countries.
Product's Review
-
Very well Review by Angelina
Rating This medicine advised by the doctor. Stunning results. (Posted on 6/14/2016)
